Head to Head Analysis: Kyverna Therapeutics (KYTX) & The Competition

Kyverna Therapeutics (NASDAQ:KYTX) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Kyverna Therapeutics to related businesses based on the strength of its risk, valuation, profitability, earnings, analyst recommendations, dividends and institutional ownership.

Risk and Volatility

Kyverna Therapeutics has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics’ rivals have a beta of -4.48, suggesting that their average share price is 548% less volatile than the S&P 500.

Profitability

This table compares Kyverna Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-51.12%	-37.91%
Kyverna Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Earnings and Valuation

This table compares Kyverna Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyverna Therapeutics	$7.03 million	-$60.37 million	-0.53
Kyverna Therapeutics Competitors	$575.27 million	-$70.96 million	0.04

Kyverna Therapeutics’ rivals have higher revenue, but lower earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Kyverna Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	0	1	5	1	3.00
Kyverna Therapeutics Competitors	1950	5423	14013	300	2.58

Kyverna Therapeutics currently has a consensus target price of $18.33, suggesting a potential upside of 901.82%. As a group, “Biological products, except diagnostic” companies have a potential upside of 130.92%. Given Kyverna Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than its rivals.

Summary

Kyverna Therapeutics beats its rivals on 9 of the 13 factors compared.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.